title: Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia.
abstract: To ascertain the clinical implications of high hyperdiploid (HH; 49-65 chromosomes) and triploid/tetraploid (TT; >65 chromosomes) adult acute myeloid leukemia (AML), all such cases were retrieved from the Swedish AML Registry. Of the 3,654 cytogenetically informative cases diagnosed between January 1997 and May 2014, 68 (1.9%) were HH (n = 50)/TT (n = 18). Patients with HH/TT were older than those with intermediate risk (IR) AML (median 71 years vs. 67 years; P = 0.042) and less often had de novo AML (63% vs. 79%; P = 0.004); no such differences were observed between HH/TT and complex karyotype (CK) AML. The overall survival (OS) was similar between patients with HH/TT and CK AML (median 0.9 years vs. 0.6 years; P = 0.082), whereas OS was significantly longer (median 1.6 years; P = 0.028) for IR AML. The OS was shorter for cases with HH than with TT (median 0.6 years vs. 1.4 years; P = 0.032) and for HH/TT AMLs with adverse abnormalities (median 0.8 years vs. 1.1 years; P = 0.044). In conclusion, HH/TT AML is associated with a poor outcome, but chromosome numbers >65 and absence of adverse aberrations seem to translate into a more favorable prognosis. Thus, HH/TT AMLs are clinically heterogeneous and should not automatically be grouped as high risk.
authors.affiliation: Department of Hematology and Vascular Disease, Skåne University Hospital, Lund, Sweden.|Stem Cell Center, Lund University, Lund, Sweden.
authors.forename: Vladimir
authors.identifier: http://orcid.org/0000-0002-1782-4423
authors.initials: V
authors.lastname: Lazarevic
authors.affiliation: Epidemiology and Registry Center in South Sweden, Skåne University Hospital, Lund, Sweden.
authors.forename: Aldana
authors.initials: A
authors.lastname: Rosso
authors.affiliation: Department of Hematology and Vascular Disease, Skåne University Hospital, Lund, Sweden.|Stem Cell Center, Lund University, Lund, Sweden.
authors.forename: Gunnar
authors.initials: G
authors.lastname: Juliusson
authors.affiliation: Department of Hematology, Linköping University Hospital, Linköping, Sweden.
authors.forename: Petar
authors.initials: P
authors.lastname: Antunovic
authors.affiliation: Department of Medicine, Division of Hematology Stockholm and Huddinge, Karolinska University Hospital, Karolinska, Sweden.
authors.forename: Åsa
authors.initials: Å
authors.lastname: Rangert-Derolf
authors.affiliation: Department of Medicine, Division of Hematology Stockholm and Huddinge, Karolinska University Hospital, Karolinska, Sweden.
authors.forename: Sören
authors.initials: S
authors.lastname: Lehmann
authors.affiliation: Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
authors.forename: Lars
authors.initials: L
authors.lastname: Möllgård
authors.affiliation: Department of Medicine, School of Health and Medical Sciences, Örebro University Hospital, Örebro, Sweden.
authors.forename: Bertil
authors.initials: B
authors.lastname: Uggla
authors.affiliation: Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
authors.forename: Lovisa
authors.initials: L
authors.lastname: Wennström
authors.affiliation: Department of Radiation Sciences, Umeå University, Umeå, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Wahlin
authors.affiliation: Department of Hematology, Academic Hospital, Uppsala, Sweden.
authors.forename: Martin
authors.initials: M
authors.lastname: Höglund
authors.affiliation: Department of Clinical Genetics, University and Regional Laboratories Region Skåne, Lund, Sweden.|Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden.
authors.forename: Bertil
authors.initials: B
authors.lastname: Johansson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011003:Ploidies; D011379:Prognosis; D012042:Registries; D012306:Risk; D016019:Survival Analysis; D013548:Sweden
chemical_list: D000970:Antineoplastic Agents